Cadasil Clinical Trial
Official title:
MRI Study of Blood-brain Barrier Function in CADASIL
Diffusion prepared pseudo-continuous ASL (DP-pCASL) is a newly proposed MRI method to noninvasively measure the function of blood-brain barrier (BBB). The investigators aim to investigate whether the water exchange rate across the BBB, estimated with DP-pCASL, is changed in patients with CADASIL, and to analyze the association between BBB water exchange rate and MRI/clinical features in these patients.
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by NOTCH3 gene mutations, is the most frequent monogenic type of hereditary cerebral small vessel disease (CSVD). The unique pathophysiological mechanisms that small vessel disorders in CADASIL are caused by genetic mutations and that the majority of patients do not combine cerebrovascular disease risk factors make CADASIL an ideal model for studying CSVD, and the imaging findings on CADASIL can be used to diagnose and investigate the etiology of CSVD. While abnormalities in the cerebrovascular structure and hemodynamics have been well demonstrated in CADASIL, the abnormality of the BBB remains controversial. One DCE-MRI study suggested an increase in BBB permeability to gadolinium contrast in CADASIL, whereas no abnormality of BBB was found in subsequent studies in mouse models and patients. The aim of this study was to assess whether BBB function is abnormal in patients with CADASIL using DP-pCASL, which is more sensitive to subtle changes in the BBB compared to DCE-MRI. The investigators hypothesized that the BBB water exchange rate (kw) is reduced in patients with CADASIL compared to controls as assessed by DP-pCASL and that the degree of reduction in BBB water exchange rate correlates with the severity of disease in patients with CADASIL. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT03724136 -
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
|
N/A | |
| Recruiting |
NCT05755997 -
CERebrolysin In CADASIL
|
Phase 2 | |
| Recruiting |
NCT06148051 -
AusCADASIL: An Australian Cohort of CADASIL
|
||
| Recruiting |
NCT04310098 -
CADASIL Registry Study
|
||
| Completed |
NCT01114815 -
Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
|
N/A | |
| Recruiting |
NCT05677880 -
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
|
||
| Recruiting |
NCT02795052 -
Neurologic Stem Cell Treatment Study
|
N/A | |
| Completed |
NCT02837354 -
The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage?
|
N/A | |
| Recruiting |
NCT01361763 -
Safety Study of Dabigatran in CADASIL
|
Phase 2 | |
| Completed |
NCT02071784 -
Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
|
||
| Completed |
NCT06072118 -
Adrenomedullin for CADASIL
|
Phase 2 | |
| Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
| Recruiting |
NCT05473637 -
Taiwan Associated Genetic and Nongenetic Small Vessel Disease
|
||
| Enrolling by invitation |
NCT02032225 -
Generation of a Cellular Model of CADASIL From Skin Fibroblasts
|
N/A | |
| Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
| Active, not recruiting |
NCT04658823 -
Efficacy and Safety of Tocotrienols in CADASIL
|
Phase 2 | |
| Withdrawn |
NCT04334408 -
Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL
|
Phase 2 | |
| Recruiting |
NCT05734378 -
Prognosis of Cerebral Small Vessel Disease
|
||
| Recruiting |
NCT05491980 -
Florida Cerebrovascular Disease Biorepository and Genomics Center
|
||
| Recruiting |
NCT04036084 -
Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy
|